Escala Secures $4.5M in Funding to Accelerate Global Expansion of Its FDA-Approved Medical Device
MWN-AI** Summary
Escala Medical Ltd., a pioneering FemTech company based in Israel, has successfully secured $4.5 million in funding to bolster its global expansion efforts for its FDA-approved medical device addressing Pelvic Organ Prolapse (POP). This funding round, which included significant participation from the EIC Fund and private investors from both the U.S. and Israel, follows a €2.5 million grant awarded through the EIC Accelerator program in October 2023.
The capital will primarily be directed toward enhancing Escala's commercial footprint in the United States, where their flagship device launched in 2023 has already facilitated hundreds of successful procedures. Additionally, the funding will aid preparations for market entry into Europe, contingent upon receiving CE approval, and support further international growth efforts, particularly through a newly brokered distribution agreement with a partner in Singapore to cover Southeast Asia.
CEO Dr. Edit Goldberg expressed the significance of this funding milestone, stating it validates their mission to broaden the reach of their innovative technology for women suffering from organ prolapse. The EIC Fund's contributions, praised by Dr. Goldberg and Chair Robert D. Auerbach, reflect a strong endorsement of Escala's vision and capabilities in revolutionizing women's health treatment.
The EIC Fund, associated with the European Commission, seeks to support companies that are at the forefront of developing disruptive technologies, with a particular emphasis on empowering female entrepreneurs and bridging the innovation gap across EU countries.
Escala is positioned for substantial growth in 2025 and beyond, with a direct sales team already operational in the U.S. and a commitment to changing the care paradigm for pelvic organ prolapse globally.
MWN-AI** Analysis
Escala Medical Ltd.'s recent achievement in securing $4.5 million in funding underscores a significant validation of its innovative approach to Pelvic Organ Prolapse (POP) treatment. With both the EIC Fund and private investors backing the company, this funding round positions Escala favorably for accelerated growth in the medical device sector, particularly in the thriving FemTech market.
The funds will primarily be allocated toward expanding commercial operations in the U.S., where Escala’s Mendit device has already received FDA approval. The device's successful track record, with hundreds of procedures conducted since its launch, reflects a strong initial market acceptance. With ongoing clinical performance data supporting its efficacy, investors may consider this a compelling opportunity given the projected increase in demand for effective, accessible women's health solutions.
Moreover, Escala's international growth strategy, notably preparation for entry into Europe and partnerships in Southeast Asia, highlights its ambition to become a global player in women’s health. The CE approval process is critical, and success in this area could substantially diversify revenue streams and mitigate risks associated with dependence on a single market.
Investors should closely monitor Escala's progress in meeting regulatory requirements and the effectiveness of its marketing strategies. As the other major counties approach their own market saturation regarding existing treatments for POP, Escala’s unique solution could capture significant market share.
Given the company's focus on transforming treatment paradigms and expanding access to women's health solutions, Escala represents a noteworthy investment opportunity, particularly as the FemTech sector continues to gain traction globally. Analysts recommend considering Escala as a contender for inclusion in portfolios aimed at benefiting from healthcare innovation and social impact investment.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Co-financing by the EIC Fund to ramp up women's health solution to POP
MISGAV, Israel , June 30, 2025 /PRNewswire/ -- Escala Medical Ltd. ("Escala"), a medical technology company specializing in innovative repair solutions for women with Pelvic Organ Prolapse (POP), today announced the successful completion of a $4.5 million funding round. The investment included the EIC Fund, following a €2.5 million grant awarded to Escala in October 2023 through the prestigious EIC Accelerator program. The round also included participation from private investors in the United States and Israel .
The funds will be used to expand Escala's commercial operations in the U.S., where the company's flagship device has been FDA-approved and commercially launched in 2023. To date, hundreds of successful procedures have been performed using the device. The funding will also support preparations for market entry into Europe , pending CE approval, as well as additional international growth through a newly signed distribution agreement with a Singapore -based partner covering Southeast Asia .
"This funding marks an important milestone as we continue to scale our operations and bring our breakthrough technology to more women worldwide," stated Dr. Edit Goldberg, CEO of Escala. "We're proud to have the support of the EIB and our private investors, and we remain committed to advancing the next generation of our Mendit device to improve outcomes and expand access to millions of women worldwide who suffer from organ prolapse."
"Being selected for the EIC Accelerator and receiving both a grant and equity investment from the EIC Fund is a major vote of confidence in our technology, our team, and our vision. These programs are among Europe's most prestigious and competitive — and we are honored to be among the few companies chosen," added Robert D. Auerbach , M.D., Chair of Escala.
"The EIC Fund is proud to support visionary companies like Escala. Their work exemplifies the transformative potential we aim to nurture through the EIC. This marks a significant milestone in their journey to bring much-needed innovation to women's health," said Svetoslava Georgieva , Chair of the EIC Fund Board.
Escala currently has a direct sales team of representatives operating in the U.S., and with strong clinical performance, growing international demand, Escala is positioned for significant growth in 2025 and beyond.
About Escala Medical
Escala, a FemTech medical device company, is a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY). Escala is committed to offering its groundbreaking repair alternative for women at all stages of pelvic organ prolapse. By shifting the point of care from the hospital to the doctor's office, Escala is committed to transforming the treatment paradigm for pelvic organ prolapse worldwide.
About EIC Fund
The European Innovation Council Fund from the European Commission is an agnostic Fund: it invests across all technologies and verticals, and all EU countries and countries associated to Horizon Europe. It provides the investment component of the EIC Accelerator blended finance. The European Investment Bank acts as investment adviser to the EIC Fund.
The EIC Fund aims to fill a critical financing gap and its main purpose is to support companies in the development and commercialisation of disruptive technologies, bridging with and crowding in market players, and further sharing risk by building a large network of capital providers and strategic partners suitable for co-investments and follow-on funding.
The Fund pays particular attention to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.
Photo: https://mma.prnewswire.com/media/2721711/Escala_Medical_Ltd.jpg
Media Contact:
Edit Goldberg
CEO, Escala Medical
edit@escalamedical.com
SOURCE Escala Medical Ltd.
FAQ**
How does the funding from the EIC Fund and private investors impact Escala's growth strategy, especially in relation to its parent company, Trendlines Group Ltd TRNGF?
What specific plans does Escala have for using the $4.5 million funding to accelerate its market entry into Europe and other international markets?
Can you elaborate on the competitive advantage of Escala's FDA-approved Mendit device in comparison to existing treatments for Pelvic Organ Prolapse, particularly as part of Trendlines Group Ltd TRNGF's portfolio?
How does Escala plan to utilize the support from the EIC Accelerator to enhance its product development and commercialization efforts, in alignment with Trendlines Group Ltd TRNGF's objectives?
**MWN-AI FAQ is based on asking OpenAI questions about Trendlines Group Ltd (OTC: TRNGF).
NASDAQ: TRNGF
TRNGF Trading
0.0% G/L:
$0.03 Last:
320,000 Volume:
$0.03 Open:
